We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
GeneGo Awarded NIH Grant to Develop Pharmacogenomics Software Suite
News

GeneGo Awarded NIH Grant to Develop Pharmacogenomics Software Suite

GeneGo Awarded NIH Grant to Develop Pharmacogenomics Software Suite
News

GeneGo Awarded NIH Grant to Develop Pharmacogenomics Software Suite

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "GeneGo Awarded NIH Grant to Develop Pharmacogenomics Software Suite"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

GeneGo, Inc. has announced that it has been awarded a grant to develop an integrated systems pharmacology platform for pharmacogenomic research.

The SBIR grant, funded through the innovations in biomedical computational science and technology initiative, will be used to develop a database and systems biology tool-set specifically designed for the study of mutations and sequence heterogeneity in human genes and their controlling regions, as well as the biological consequences of sequence variations on disease susceptibility and drug response.

“Genome-wide association studies and next-generation resequencing projects are already generating vast amounts of data on genetic factors contributing to disease susceptibility and variability in the pharmacological and toxicological effects of drugs,” said Richard Brennan, Director of Toxicology at GeneGo and PI on the grant.

Brennan continued, “What is lacking are powerful tools for researchers to be able to link these sequence variations to the specific mechanisms and biological pathways driving idiosyncratic outcomes. The product will smooth the progress of personalized medicine by facilitating the application of personal genetic profiling to identify optimal therapeutic strategies.”

“Receiving such a prestigious grant award is another example of the cutting edge research at GeneGo that sets us apart from other companies,” said Julie Bryant, GeneGo’s VP of Business Development. “It allows us to develop novel tools and databases to help our customers mine important content from the literature, analyze their data and test their hypotheses.”
Advertisement